Aging Biotech Info is a Curated List of Companies in the Longevity Industry
Karl Pfleger is one of the small community of angel investors and philanthropists who collectively initially supported the first rejuvenation biotechnology companies to emerge in this present generation of the longevity industry. Here he is performing the public service of publishing a curated list of biotechnology companies in the industry, startups that are either definitively or at least arguably working on a means to intervene in important mechanisms of aging, along with their targets and progress to date. That there are still fewer than 100 such companies indicates that this is very much an industry in its initial growth phase - but growth is certainly happening. The sizable pools of venture funding dedicated to the longevity industry, such as Juvenescence and Life Biosciences are attracting new entrepreneurs, and the scientific community is starting to realize that the prospects for advancing their research programs into clinical translation have greatly improved these past few years.
Chronic diseases of aging have over the past century taken over from infectious diseases as the predominant causes of death and suffering. The science of aging has shown over the past few decades that certain slow biological changes collectively underlie most (if not all) chronic diseases. The aging and longevity field, the understanding of these slow changes and how to interfere with them, is currently a small part of the overall medical, healthcare, and biotech spaces, but the efficiency of targeting the underlying causes of multiple diseases will rapidly cause aging to grow to become a much larger portion.
The aging and longevity field has recently grown to the point where it is difficult to follow important developments, even for insiders. There are books, journals, and blogs, but few sources of structured information to refer to for broader context or to consult for targeted inquiries, particularly few focused narrowly on aging defined as the underlying molecular causes of multiple age-related diseases.
As an especially important example, the internet previously had no reasonably comprehensive and precise list of companies with therapies or diagnostics for underlying aging in the above sense. Some argue that aging will be a scientific, commercial, and cultural revolution to rival any others. What is even more certain is that the field is important and of interest to many, so concise ways to pay attention will be useful. This will be a living site with ongoing updates. Focus will be on content, not flashiness, with the goal being utility for the community, those interacting with it, and the wider interested public.
Any advice|hints for a stock investor?
@Andriy
If you are into public companies, you should sit on the sidelines until there is any reasonably good data to head into Phase 2 development with
The bigger names from last years IPO frenzy like Unity and ResTorBio, not to mention AgeX, are down significantly (hundreds of millions of hype) from their highs and have nowhere to go for a while until the next wave of clinical data comes in
Also, as a retail investor in these companies you are at the whim of the insiders who are in essence controlling the stock price for now - make sure you understand this for each company and why they swing so much daily - https://finance.yahoo.com/quote/UBX/holders?p=UBX
@BioInvestor99
Thank you
@Bioinvestor99 - It seems a bit silly to attribute declines in a company's stock price as evidence of new unwelcome news rather than just general sector or market declines. If you are going to continue disparaging these companies at least provide some links to a relevant benchmark index to show that the prices changes are not attribuatble to sector, currency etc.
@jimofoz
Those are small caps companies with highly asymmetric information availability. They are also high risk. Don't mortgage your house to buy into them. And if you own some you will witness a rollercoaster of the stock price.
@jimofoz
Biotech investing is quite simple
Private co - Early small (angel / friends and family) investors in private biotech companies typically lose their money due to the extensive institutional PE/VC dilution that occurs getting upstream and across the "valley of death"
Public co - with the exception of "pr pumping" dynamics to keep stocks up, the stocks skyrocket at meaningful clinical events - nothing else
If you don't have the money to lose, or you think you can hold and wait like in other industries and make millions, you're in the wrong space